
Opinion|Videos|September 12, 2024
Investigational Agents for Idiopathic and Progressive Pulmonary Fibrosis
Author(s)Paul Frohna, MD, PhD
Dr Frohna discusses some therapies under investigation for idiopathic and progressive pulmonary fibrosis, including one targeting the PDE4 pathway.
Advertisement
What are some of the pharmacotherapies being investigated in phase 3 clinical trials for IPF/PPF, and what have the data shown thus far?
Phosphodiesterase (PDE) 4 inhibition is currently being investigated in IPF/PPF. What is the rationale for studying this pathway?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
FDA approves first treatment for chronic hepatitis D virus
2
Cancer patients taking GLP-1s less likely to develop advanced disease | ASCO 2026
3
Recent COVID vaccination cuts household transmission by half
4
Priority review granted for Kerendia in Type 1 diabetes and kidney disease
5






















